<!--?xml version="1.0" encoding="utf-8"?--><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"><html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="plosone"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC4368747/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Validation of a Rapid and Sensitive LC-MS/MS Method for Determination of Exemestane and Its Metabolites, 17β-Hydroxyexemestane and 17β-Hydroxyexemestane-17-O-β-D-Glucuronide: Application to Human Pharmacokinetics Study</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css"><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368747/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="PLoS ONE"><meta name="citation_title" content="Validation of a Rapid and Sensitive LC-MS/MS Method for Determination of Exemestane and Its Metabolites, 17β-Hydroxyexemestane and 17β-Hydroxyexemestane-17-O-β-D-Glucuronide: Application to Human Pharmacokinetics Study"><meta name="citation_authors" content="Ling-Zhi Wang, Sok-Hwei Goh, Andrea Li-Ann Wong, Win-Lwin Thuya, Jie-Ying Amelia Lau, Seow-Ching Wan, Soo-Chin Lee, Paul C. Ho, Boon-Cher Goh"><meta name="citation_date" content="2015"><meta name="citation_issue" content="3"><meta name="citation_volume" content="10"><meta name="citation_doi" content="10.1371/journal.pone.0118553"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC4368747/?report=abstract"><meta name="citation_pmid" content="25793887"><meta name="DC.Title" content="Validation of a Rapid and Sensitive LC-MS/MS Method for Determination of Exemestane and Its Metabolites, 17β-Hydroxyexemestane and 17β-Hydroxyexemestane-17-O-β-D-Glucuronide: Application to Human Pharmacokinetics Study"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="Public Library of Science"><meta name="DC.Contributor" content="Ling-Zhi Wang"><meta name="DC.Contributor" content="Sok-Hwei Goh"><meta name="DC.Contributor" content="Andrea Li-Ann Wong"><meta name="DC.Contributor" content="Win-Lwin Thuya"><meta name="DC.Contributor" content="Jie-Ying Amelia Lau"><meta name="DC.Contributor" content="Seow-Ching Wan"><meta name="DC.Contributor" content="Soo-Chin Lee"><meta name="DC.Contributor" content="Paul C. Ho"><meta name="DC.Contributor" content="Boon-Cher Goh"><meta name="DC.Date" content="2015"><meta name="DC.Identifier" content="10.1371/journal.pone.0118553"><meta name="DC.Language" content="en"><meta property="og:title" content="Validation of a Rapid and Sensitive LC-MS/MS Method for Determination of Exemestane and Its Metabolites, 17β-Hydroxyexemestane and 17β-Hydroxyexemestane-17-O-β-D-Glucuronide: Application to Human Pharmacokinetics Study"><meta property="og:type" content="article"><meta property="og:description" content="A novel, rapid and sensitive liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the evaluation of exemestane pharmacokinetics and its metabolites, 17β-dihydroexemestane (active metabolite) and 17β-dihydroexemestane-17-O-β-D-glucuronide ..."><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368747/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><meta name="ncbi_feature" content="associated_data"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'"><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css"><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-plosone.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content=""><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC4368747/epub/"><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC4368747/pdf/pone.0118553.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="8A1BFC58E8E38FE10000000006D406D4.m_8">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print"><script async="1" src="https://www.google-analytics.com/analytics.js"></script><style type="text/css">.ncbi-alerts { background: none repeat scroll 0% 0% #671414;color: #fff;padding: .231em 1.231em;}.ncbi-alerts p { color: #fff; }.ncbi-alerts a, .ncbi-alerts a:visited {color: #fff; background: none;}.ncbi-alerts p {margin: 1em 0;padding: 0 0 0 1.5em; }.ncbi-alerts p:nth-child(1) {background-image: url('/core/icons/information.png');background-position: left top;background-repeat: no-repeat }.ncbi-alerts.subclosed p:nth-child(1) {background-image: url('/core/alerts/warning.png');}.ncbi-alerts.subclosed p { padding-left: 2em;}.ncbi-alerts.pubmed, .ncbi-alerts.pubmed p {background-color: #97B0C8; color: #000;}.ncbi-alerts a { text-decoration: underline !important; }.ncbi-alerts.pubmed a, .ncbi-alerts.pubmed a:visited { color: #000; }.ncbi-alerts, .ncbi-alerts p {background-color: #97B0C8; color: #000;}.ncbi-alerts a, .ncbi-alerts a:visited { color: #000; }</style></head>
    <body class="article" id="ui-ncbiexternallink-4">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	&lt;p class="nojs"&gt;
	&lt;strong&gt;Warning:&lt;/strong&gt;
	The NCBI web site requires JavaScript to function. 
	&lt;a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank"&gt;more...&lt;/a&gt;
	&lt;/p&gt;
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi" style="top: -0.4em;"><iframe src="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/emyncbi.fcgi?cmd=htmlportal&amp;currenturl=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4368747%2F" style="border:none; height:2.5em; width:40em;" scrolling="no"></iframe></div></div>
                            <div class="header" style="margin-bottom: 0px;">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="jig-ncbiclearbutton-wrap ui-ncbiclearbutton-wrap box-shadow"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" aria-haspopup="true" aria-autocomplete="list" role="textbox"><a class="reset" href="#" style="visibility: hidden;"><img src="/core/jig/1.14.8/img/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="archive"><a class="navlink" href="/pmc/journals/440/">PLoS One</a></li><li class="issue-page"><a class="navlink" href="/pmc/issues/250028/">v.10(3); 2015</a></li><li class="accid">PMC4368747</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-plosone.gif" alt="Logo of plosone" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,0,438,55" alt="PLoS One" title="PLoS One" href="http://www.plosone.org/" ref="reftype=publisher&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="0,56,104,74" alt="View this Article" title="View this Article" href="//dx.doi.org/10.1371/journal.pone.0118553" ref="reftype=publisher&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Content%20Provider%7CArticle%7CFullText" target="pmc_ext"><area shape="rect" coords="106,56,202,74" alt="Submit to PLoS" title="Submit to PLoS" href="http://www.plosone.org/static/checklist.action" ref="reftype=publisher&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="204,56,302,74" alt="Get E-mail Alerts" title="Get E-mail Alerts" href="http://journals.plos.org/alerts" ref="reftype=publisher&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="304,56,374,74" alt="Contact Us" title="Contact Us" href="http://www.plosone.org/static/contact.action" ref="reftype=publisher&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="440,0,500,55" alt="Public Library of Science (PLoS)" title="Public Library of Science (PLoS)" href="http://www.plos.org/" ref="reftype=publisher&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" id="ui-ncbiinpagenav-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span role="menubar"><a href="#" role="menuitem" aria-expanded="false" aria-haspopup="true">PLoS One</a></span>. 2015; 10(3): e0118553. </span></div><div><span class="fm-vol-iss-date">Published online 2015 Mar 20. </span>  <span class="doi">doi:&nbsp;<a href="//dx.doi.org/10.1371%2Fjournal.pone.0118553" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1371/journal.pone.0118553</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC4368747</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/25793887">25793887</a></div></div></div></div><h1 class="content-title">Validation of a Rapid and Sensitive LC-MS/MS Method for Determination of Exemestane and Its Metabolites, 17β-Hydroxyexemestane and 17β-Hydroxyexemestane-17-O-β-D-Glucuronide: Application to Human Pharmacokinetics Study</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Wang%20LZ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887" class="affpopup" co-rid="_co_idm140359729699280" co-class="co-affbox">Ling-Zhi Wang</a>,<sup>
1
,</sup><sup>
2
,</sup><sup>*</sup> <a href="/pubmed/?term=Goh%20SH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887" class="affpopup" co-rid="_co_idm140359725403824" co-class="co-affbox">Sok-Hwei Goh</a>,<sup>
3
</sup> <a href="/pubmed/?term=Wong%20AL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887" class="affpopup" co-rid="_co_idm140359725401680" co-class="co-affbox">Andrea Li-Ann Wong</a>,<sup>
1
,</sup><sup>
4
</sup> <a href="/pubmed/?term=Thuya%20WL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887" class="affpopup" co-rid="_co_idm140359726403120" co-class="co-affbox">Win-Lwin Thuya</a>,<sup>
1
</sup> <a href="/pubmed/?term=Lau%20JY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887" class="affpopup" co-rid="_co_idm140359726400752" co-class="co-affbox">Jie-Ying Amelia Lau</a>,<sup>
1
</sup> <a href="/pubmed/?term=Wan%20SC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887" class="affpopup" co-rid="_co_idm140359726398384" co-class="co-affbox">Seow-Ching Wan</a>,<sup>
1
</sup> <a href="/pubmed/?term=Lee%20SC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887" class="affpopup" co-rid="_co_idm140359729990112" co-class="co-affbox">Soo-Chin Lee</a>,<sup>
1
,</sup><sup>
4
</sup> <a href="/pubmed/?term=Ho%20PC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887" class="affpopup" co-rid="_co_idm140359729986624" co-class="co-affbox">Paul C. Ho</a>,<sup>
3
</sup> and  <a href="/pubmed/?term=Goh%20BC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887" class="affpopup" co-rid="_co_idm140359764712240" co-class="co-affbox">Boon-Cher Goh</a><sup>
1
,</sup><sup>
2
,</sup><sup>
4
,</sup><sup>*</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140359729699280"><h3 class="no_margin">Ling-Zhi Wang</h3><p>  <sup>1</sup>  Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599, Singapore,   </p><p>  <sup>2</sup>  Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore 117599, Singapore,   </p><div>Find articles by <a href="/pubmed/?term=Wang%20LZ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887">Ling-Zhi Wang</a></div></div><div id="_co_idm140359725403824"><h3 class="no_margin">Sok-Hwei Goh</h3><p>  <sup>3</sup>  Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore,   </p><div>Find articles by <a href="/pubmed/?term=Goh%20SH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887">Sok-Hwei Goh</a></div></div><div id="_co_idm140359725401680"><h3 class="no_margin">Andrea Li-Ann Wong</h3><p>  <sup>1</sup>  Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599, Singapore,   </p><p>  <sup>4</sup>  Department of Haematology &amp; Oncology, National University Health System, Singapore 119074, Singapore,   </p><div>Find articles by <a href="/pubmed/?term=Wong%20AL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887">Andrea Li-Ann Wong</a></div></div><div id="_co_idm140359726403120"><h3 class="no_margin">Win-Lwin Thuya</h3><p>  <sup>1</sup>  Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599, Singapore,   </p><div>Find articles by <a href="/pubmed/?term=Thuya%20WL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887">Win-Lwin Thuya</a></div></div><div id="_co_idm140359726400752"><h3 class="no_margin">Jie-Ying Amelia Lau</h3><p>  <sup>1</sup>  Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599, Singapore,   </p><div>Find articles by <a href="/pubmed/?term=Lau%20JY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887">Jie-Ying Amelia Lau</a></div></div><div id="_co_idm140359726398384"><h3 class="no_margin">Seow-Ching Wan</h3><p>  <sup>1</sup>  Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599, Singapore,   </p><div>Find articles by <a href="/pubmed/?term=Wan%20SC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887">Seow-Ching Wan</a></div></div><div id="_co_idm140359729990112"><h3 class="no_margin">Soo-Chin Lee</h3><p>  <sup>1</sup>  Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599, Singapore,   </p><p>  <sup>4</sup>  Department of Haematology &amp; Oncology, National University Health System, Singapore 119074, Singapore,   </p><div>Find articles by <a href="/pubmed/?term=Lee%20SC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887">Soo-Chin Lee</a></div></div><div id="_co_idm140359729986624"><h3 class="no_margin">Paul C. Ho</h3><p>  <sup>3</sup>  Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore,   </p><div>Find articles by <a href="/pubmed/?term=Ho%20PC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887">Paul C. Ho</a></div></div><div id="_co_idm140359764712240"><h3 class="no_margin">Boon-Cher Goh</h3><p>  <sup>1</sup>  Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599, Singapore,   </p><p>  <sup>2</sup>  Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore 117599, Singapore,   </p><p>  <sup>4</sup>  Department of Haematology &amp; Oncology, National University Health System, Singapore 119074, Singapore,   </p><div>Find articles by <a href="/pubmed/?term=Goh%20BC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25793887">Boon-Cher Goh</a></div></div></div></div><div class="contrib-group half_rhythm fm-editor">Junxuan Lu, <span class="fm-role">Academic Editor</span><sup></sup></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140359726295760_ai idm140359729699408_ai idm140359761886752_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140359726295760_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140359726295760_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140359726295760_ai" style="display:none"><div class="fm-affl" lang="en" id="aff001">  <sup>1</sup>  Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599, Singapore,   </div><div class="fm-affl" lang="en" id="aff002">  <sup>2</sup>  Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore 117599, Singapore,   </div><div class="fm-affl" lang="en" id="aff003">  <sup>3</sup>  Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore,   </div><div class="fm-affl" lang="en" id="aff004">  <sup>4</sup>  Department of Haematology &amp; Oncology, National University Health System, Singapore 119074, Singapore,   </div><div class="fm-affl" lang="en" id="edit1">  Texas Tech Univ School of Pharmacy, UNITED STATES,   </div><div id="coi001"><strong>Competing Interests: </strong>The authors have declared that no competing interests exist.</div><div><p id="__p2" class="p p-first-last">Conceived and designed the experiments: WLZ WA GBC PCH LSC. Performed the experiments: WLZ GSH TWL LJA WSC. Analyzed the data: WLZ WA GSH PCH. Contributed reagents/materials/analysis tools: GBC WA LSC. Wrote the paper: WLZ GSH PCH WA.</p></div><div id="cor001">* E-mail: <a href="mailto:dev@null" data-email="gs.ude.sun@lwisc" class="oemail">gs.ude.sun@lwisc</a> (LZW); <a href="mailto:dev@null" data-email="gs.ude.sun@cbgchp" class="oemail">gs.ude.sun@cbgchp</a> (BCG)</div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm140359726295760_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2014 Oct 30; Accepted 2015 Jan 20.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm140359726295760_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> © 2015 Wang et al</div><div class="license half_rhythm">This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC4368747/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 class="ui-helper-clearfix" id="ui-ncbiinpagenav-heading-3">Associated Data</h2><dl data-length="39" class="box-data-avail whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-avl-stmnt" data-ga-action="click_feat_toggler" data-ga-label="Data Availability Statement" class="pmctoggle">Data Availability Statement</a></dt><dd id="data-avl-stmnt" style="display: none;"><p>All relevant data are within the paper.</p></dd></dl></div><div id="idm140359761133280" lang="en" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140359761133280title">Abstract</h2><!--article-meta--><div><p id="__p3" class="p p-first-last">A novel, rapid and sensitive liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the evaluation of exemestane pharmacokinetics and its metabolites, 17β-dihydroexemestane (active metabolite) and 17β-dihydroexemestane-17-O-β-D-glucuronide (inactive metabolite) in human plasma. Their respective D3 isotopes were used as internal standards. Chromatographic separation of analytes was achieved using Thermo Fisher BDS Hypersil C18 analytic HPLC column (100 × 2.1 mm, 5 μm). The mobile phase was delivered at a rate of 0.5 mL/min by gradient elution with 0.1 % aqueous formic acid and acetonitrile. The column effluents were detected by API 4000 triple quadrupole mass spectrometer using electrospray ionisation (ESI) and monitored by multiple reaction monitoring (MRM) in positive mode. Mass transitions 297 &gt; 121 <em>m/z</em>, 300 &gt; 121 <em>m/z</em>, 299 &gt; 135 <em>m/z</em>, 302 &gt; 135 <em>m/z</em>, 475 &gt; 281 <em>m/z</em>, and 478 &gt; 284 <em>m/z</em> were monitored for exemestane, exemestane-d3, 17β-dihydroexemestane, 17β-dihydroexemestane-d3, 17β-dihydroexemestane-17-O-β-D-glucuronide, and 17β-dihydroexemestane-17-O-β-D-glucuronide-d3 respectively. The assay demonstrated linear ranges of 0.4 – 40.0 ng/mL, for exemestane; and 0.2 – 15.0 ng/mL, for 17β-dihydroexemestane and 17β-dihydroexemestane-17-O-β-D-glucuronide, with coefficient of determination (r<sup>2</sup>) of &gt; 0.998. The precision (coefficient of variation) were ≤10.7%, 7.7% and 9.5% and the accuracies ranged from 88.8 to 103.1% for exemestane, 98.5 to 106.1% for 17β-dihydroexemestane and 92.0 to 103.2% for 17β-dihydroexemestane-17-O-β-D-glucuronide. The method was successfully applied to a pharmacokinetics/dynamics study in breast cancer patients receiving exemestane 25mg daily orally. For a representative patient, 20.7% of exemestane in plasma was converted into 17β-dihydroexemestane and 29.0% of 17β-dihydroexemestane was inactivated as 17β-dihydroexemestane-17-O-β-D-glucuronide 24 hours after ingestion of exemestane, suggesting that altered 17-dihydroexemestane glucuronidation may play an important role in determining effect of exemestane against breast cancer cells.</p></div></div><div id="sec001" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="sec001title">Introduction</h2><p id="__p5" class="p p-first">Breast cancer has remained the most common cancer among females in Singapore over the last forty years.[<a href="#pone.0118553.ref001" rid="pone.0118553.ref001" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752933" role="button" aria-expanded="false" aria-haspopup="true">1</a>] Currently, the role of exemstane (Exe) in breast cancer treatment is evolving; traditionally used as an adjuvant medication for hormone receptor positive breast cancer, new trials have investigated its role as adjuvant medication in metastatic cancer and preventive medication in high-risk women.[<a href="#pone.0118553.ref002" rid="pone.0118553.ref002" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752938" role="button" aria-expanded="false" aria-haspopup="true">2</a>–<a href="#pone.0118553.ref006" rid="pone.0118553.ref006" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752936" role="button" aria-expanded="false" aria-haspopup="true">6</a>] In the adjuvant setting, Exe, similar to the other third-generation compounds, revealed improved relapse-free survival compared to tamoxifen monotherapy when administered as sequential therapy.[<a href="#pone.0118553.ref007" rid="pone.0118553.ref007" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752931" role="button" aria-expanded="false" aria-haspopup="true">7</a>] Exe is the first steroidal aromatase inhibitor (AI) which inhibits <em>in vivo</em> formation of oestrogens (estrone and estradiol), thereby reducing stimulation for breast cancer cell proliferation.[<a href="#pone.0118553.ref008" rid="pone.0118553.ref008" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752932" role="button" aria-expanded="false" aria-haspopup="true">8</a>] Variability in response and side effect profile has been observed in patients in many AI clinical trials and the underlying mechanism remains undefined.[<a href="#pone.0118553.ref009" rid="pone.0118553.ref009" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752929" role="button" aria-expanded="false" aria-haspopup="true">9</a>–<a href="#pone.0118553.ref013" rid="pone.0118553.ref013" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752937" role="button" aria-expanded="false" aria-haspopup="true">13</a>] Recently, the major metabolic pathway of Exe has been delineated; as a reduction of double bond in 17 keto group via aldo-keto reductase (AKR) to form 17β-dihydroexemestane (17DhExe) is a major pathway for exemestane phase I metabolism. [<a href="#pone.0118553.ref014" rid="pone.0118553.ref014" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752935" role="button" aria-expanded="false" aria-haspopup="true">14</a>] In addition, 17DhExe has been reported to be an active metabolite which is subsequently inactivated by glucuronidation to 17β-dihydroexemestane-17-O-β-D-glucuronide (Exe17Oglu). [<a href="#pone.0118553.ref015" rid="pone.0118553.ref015" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752927" role="button" aria-expanded="false" aria-haspopup="true">15</a>, <a href="#pone.0118553.ref016" rid="pone.0118553.ref016" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752940" role="button" aria-expanded="false" aria-haspopup="true">16</a>] Inactivation of 17DhExe is catalysed by the enzyme UDP-gluconoryltransferase 2B17 (UGT2B17). Exemestane’s major metabolism pathway is summarized in <a href="/pmc/articles/PMC4368747/figure/pone.0118553.g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone.0118553.g001" rid-ob="ob-pone.0118553.g001" co-legend-rid="lgnd_pone.0118553.g001"><span>Fig. 1</span></a>. It has also been identified that 60–70% of Asians suffer from homozygous gene deletion of UGT2B17, which can result in reduced glucuronidation of 17DhExe and increased exposure to this active metabolite. [<a href="#pone.0118553.ref016" rid="pone.0118553.ref016" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752934" role="button" aria-expanded="false" aria-haspopup="true">16</a>] Therefore, simultaneous quantification of Exe, 17DhExe, and Exe17Oglu can aid in determination of the impact of homozygous UGT2B17 gene deletion on the <em>in vivo</em> metabolic profile of Exe. [<a href="#pone.0118553.ref017" rid="pone.0118553.ref017" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752928" role="button" aria-expanded="false" aria-haspopup="true">17</a>]</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone.0118553.g001" co-legend-rid="lgnd_pone.0118553.g001"><a href="/pmc/articles/PMC4368747/figure/pone.0118553.g001/" target="figure" rid-figpopup="pone.0118553.g001" rid-ob="ob-pone.0118553.g001"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140359766589808" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.
Object name is pone.0118553.g001.jpg" title="An external file that holds a picture, illustration, etc.
Object name is pone.0118553.g001.jpg" src="/pmc/articles/PMC4368747/bin/pone.0118553.g001.jpg"></div></a><div id="largeobj_idm140359766589808" class="largeobj-link align_right" style="display: none;"><a href="/pmc/articles/PMC4368747/figure/pone.0118553.g001/" target="figure" rid-figpopup="pone.0118553.g001" rid-ob="ob-pone.0118553.g001"></a><a target="object" href="/pmc/articles/PMC4368747/figure/pone.0118553.g001/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_pone.0118553.g001"><div><a class="figpopup" href="/pmc/articles/PMC4368747/figure/pone.0118553.g001/" target="figure" rid-figpopup="pone.0118553.g001" rid-ob="ob-pone.0118553.g001">Fig 1</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Exemestane major metabolism pathway.</strong></div></div></div><p id="__p6" class="p p-last">To date, two reported analytical methods have been developed and validated for determination of Exe and 17DhExe; one is a HPLC-UV assay with low limit of quantification (LLOQ) of 10 ng/mL for both parental drug and 17DhExe [<a href="#pone.0118553.ref018" rid="pone.0118553.ref018" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752939" role="button" aria-expanded="false" aria-haspopup="true">18</a>] and the other is a LC-MS/MS method with LLOQ of 0.2 ng/ml for Exe and 0.1 ng/ml for 17DhExe.[<a href="#pone.0118553.ref019" rid="pone.0118553.ref019" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_694752930" role="button" aria-expanded="false" aria-haspopup="true">19</a>] Compared to HPLC-UV method, the LC-MSMS method demonstrated superior sensitivity and specificity which are critical to accurately quantify analytes of interest. Nevertheless, no analytical method has been established to concurrently quantify Exe and its two key metabolites (17DhExe and Exe17Oglu) within one chromatographic run. This is a major research gap to determine the influence of UGT2B17 variants on the glucuronidation of 17DhExe in human plasma samples. In order to support a clinical trial of Exe in breast cancer patients in Singapore National University Hospital (NUH), a simple, novel and sensitive LC-MS/MS method was developed for determination of plasma concentrations of these three compounds simultaneously. The well-validated method has been successfully applied to determine the plasma concentrations of Exe and two important metabolites in clinical plasma samples of breast cancer patients.</p></div><div id="sec002" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="sec002title">Experimental</h2><div id="sec003" class="sec sec-first"><h3 id="sec003title">Chemicals and Reagents</h3><p id="__p7" class="p p-first">Exemestane, 17β-hydroxyexemestane, and 17β-hydroxyexemestane-17-O-β-D-glucuronide, the reference standards, were purchased from Toronto Research Chemicals Inc. (North York, Ontario, Canada). Exemestane-d3, 17β-hydroxyexemestane-d3 and 17β-hydroxyexemestane-d3–17-O-β-D-glucuronide, the stable isotope-labelled internal standards (IS), were also purchased from Toronto Research Chemicals Inc. (North York, Ontario, Canada).</p><p id="__p8">Methanol, acetonitrile and formic acid (100%, v/v) were purchased from Merck (Darmstadt, Germany). Milli-Q water from Milli-Q Plus system (Millipore, Milford, MA, USA) was used throughout the study.</p><p id="__p9" class="p p-last">Drug-free blank human plasma was obtained from healthy donors from the National University Hospital (NUH), Singapore.</p></div><div id="sec004" class="sec"><h3 id="sec004title">Chromatographic and Mass Spectrometric Conditions</h3><p id="__p10" class="p p-first">LC-MS/MS analysis was performed using an API 4000 triple quadrupole mass spectrometer (Applied Biosystems, MDS SCIEX, Ontario, Canada). The HPLC system was composed of Agilent 1100 series gradient pump, degasser, autosampler and column oven (Agilent Technologies, Germany). The data was acquired and processed using Analyst software (Version 1.4.2, Applied Biosystems, MDS SCIEX, Ontario, Canada).</p><p id="__p11">The chromatographic separation of analytes from endogenous compounds was performed on a BDS Hypersil C18 column (100 × 2.1 mm, 5 μm, Thermo Fisher Scientific, Waltham, Massachusetts, United States), which was preceded by a SecurityGuard cartridge (4.0 × 3.0 mm, Phenomenex, CA, United States). The column and the autosampler were both maintained at 24°C.</p><p id="__p12" class="p p-last">The mass spectrometer was equipped with an electrospray ionisation source and it was operated in the positive ion detection mode in the multiple reaction monitoring (MRM).</p></div><div id="sec005" class="sec"><h3 id="sec005title">Preparation of Stock Solutions, Calibration and Quality Control Standards</h3><p id="__p13" class="p p-first-last">Stock solutions of Exe, Exe-d3, 17DhExe, 17DhExe-d3, Exe17Oglu and Exe17Oglu-d3 were prepared with methanol at 1.0 mg/mL. Seven standard working solutions of Exe were prepared by serial dilution with methanol to achieve concentrations of 4, 10, 20, 40, 100, 200 and 400 ng/mL. Similarly, seven standard working solutions of 17DhExe and Exe17Oglu were prepared separately by serial dilution with methanol to achieve concentrations of 2, 5, 10, 20, 40, 100, and 200 ng/mL. A working solution of IS was prepared at 100 ng/mL, for Exe-d3, 17DhExe-d3, and Exe17Oglu-d3. Three quality control (QC) working solutions of Exe were prepared by serial dilution with methanol to achieve concentrations of 30, 75, and 250 ng/mL. Similarly, three QC working solutions of 17DhExe and Exe17Oglu were prepared separately by serial dilution with methanol to achieve concentrations of 15, 40, and 100 ng/mL. All stock and working solutions were stored at 4°C.</p></div><div id="sec006" class="sec"><h3 id="sec006title">Calibrator and Quality Control Sample Preparation</h3><p id="__p14" class="p p-first-last">Five μL of each standard working solution and 10 μL of the IS working solution were placed into 1.5 mL polypropylene (PP) centrifuge tube. An aliquot of human plasma (50 μL) was added, and the PP tube was vortexed for 30 s. Proteins were precipitated by addition of 150 uL of acetonitrile subsequently and the PP tube was vortexed for another 30 s. Next, the PP tube was centrifuged at 35,000 × g for 10 min at 4°C. Thereafter, 150 μL of the supernatant was transferred to a second 1.5 mL PP tube and the supernatant dried by concentrator plus (Eppendorf) for 60 min at 45°C. The dried residue was reconstituted with 50 μL of acetonitrile—0.1% formic acid mixture (25:75, v/v) and vortexed for 30 s. After that, the tubes were centrifuged at 35,000 × g for 10 min at 4°C. Forty microliters of the resulting supernatant was transferred to a 250 μL glass insert in an autosampler vial. A volume of 30 μL was injected per run for quantitative analysis by LC-MS/MS.</p></div><div id="sec007" class="sec"><h3 id="sec007title">Construction of Standard Calibration Curve</h3><p id="__p15" class="p p-first-last">The standard calibration curves were constructed using six concentrations. The calibrators were prepared at the following concentrations: 0.4, 1.0, 2.0, 5.0, 10.0, 20.0, and 40.0 ng/mL for Exe; and 0.2, 0.5, 1.0, 2.0, 5.0, 7.5, and 15.0 ng/mL, for 17DhExe and Exe17Oglu. The standard calibration curves of Exe, 17DhExe, and Exe17Oglu were generated using the peak area ratios of Exe to Exe-d3, 17DhExe to 17DhExe-d3, and Exe17Oglu to Exe17Oglu-d3 respectively.</p></div><div id="sec008" class="sec"><h3 id="sec008title">Bioanalytical Method Validation</h3><p id="__p16" class="p p-first-last">A full method validation was performed according to guidelines for bioanalytical method validation by the United States Food and Drug Administration. [<a href="#pone.0118553.ref020" rid="pone.0118553.ref020" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">20</a>]</p></div><div id="sec009" class="sec"><h3 id="sec009title">Selectivity, Carry-over and Linearity</h3><p id="__p17" class="p p-first">Six different sources of blank human plasma were tested for interference in the selectivity test.</p><p id="__p18">Blank wash samples were analysed right after the highest concentration calibration standards, for a total of six times, in the carry-over test.</p><p id="__p19" class="p p-last">The coefficients of determination (r<sup>2</sup>) of the standard calibration curves were used in the linearity test.</p></div><div id="sec010" class="sec"><h3 id="sec010title">Accuracy and Precision</h3><p id="__p20" class="p p-first-last">The accuracy and precision were validated by analysing QC samples at nominal concentrations of 3.0, 7.5, 25.0 ng/mL for Exe; and 1.5, 4.0, 10.0 ng/mL for 17DhExe and Exe17Oglu. Intra-day accuracy and precision were determined by performing a standard calibration curve with QC samples in quintuplicate in a single run. Inter-day accuracy and precision were determined by performing standard calibration curves with QC samples on five separate days. Accuracy was calculated as a percentage of the mean value measured over the nominal value at each concentration; precision was expressed in terms of coefficient of variation (CV), defined as percentage of the standard deviation divided by the mean.</p></div><div id="sec011" class="sec"><h3 id="sec011title">Matrix Effect</h3><p id="__p21" class="p p-first">The matrix effect was validated by analysing the ratios of analytes and IS peak areas in the matrix-based tubes to those in the reference tubes. The validation was carried out on QC samples in quadruplicate at each concentration.</p><p id="__p22">For the matrix-based tube, 50 μL of blank human plasma was placed in a 1.5 mL PP tube. 150 μL of acetonitrile was added subsequently and the PP tube was vortexed for another 30 s. The PP tube was centrifuged at 35,000 × g for 10 min at 4°C. Thereafter, 150 μL of the supernatant was transferred to a second 1.5 mL PP tube. Five microliters of each QC working solution and 10 μL of the IS working solution were added, and the PP tube was vortexed for 30 s. The mixture was subsequently dried. The dried mixture was reconstituted with 50 μL of acetonitrile—0.1% formic acid mixture (25:75, v/v) and vortexed for 30 s. The reconstituted mixture was centrifuged at 35,000 × g for 10 min at 4°C. 40 μL of the reconstituted mixture was transferred to a 250 μL glass insert in an autosampler vial for analysis.</p><p id="__p23" class="p p-last">For the reference tube, the procedure was repeated with 50 μL of milliQ water replacing the blank human plasma.</p></div><div id="sec012" class="sec"><h3 id="sec012title">Recovery</h3><p id="__p24" class="p p-first">The recovery was investigated by analysing the ratios of analytes and IS peak areas in the tube spiked before extraction to those in the tube spiked after extraction. The validation was carried out on QC samples in quadruplicate at each concentration.</p><p id="__p25">For the tube spiked before extraction, the steps were carried out as in Section of Calibrator and Quality Control Sample Preparation.</p><p id="__p26" class="p p-last">For the tube spiked after extraction, the steps were carried out as in Section of Matrix Effect for the matrix-based tube.</p></div><div id="sec013" class="sec"><h3 id="sec013title">Stability</h3><p id="__p27" class="p p-first">Stability of the analytes in human plasma was determined using QC samples in triplicates at each concentration.</p><p id="__p28">(a) Short-term Temperature Stability</p><p id="__p29">Intervals of 4, 8, and 24 hours were selected for stability testing. Nine aliquots of each QC concentration were prepared in human plasma and kept on the bench-top. Three aliquots of each QC concentration were taken at each time interval after 4, 8, and 24 hours. Sample preparation, as stipulated in Section 2.4 with the exception of spiking with the standard working solutions, was then carried out to analyse the samples.</p><p id="__p30">(b) Freeze-thaw Stability</p><p id="__p31" class="p p-last">Three, six, and nine freeze-thaw cycles were selected for stability testing. For each set (i.e. three, six, and nine freeze-thaw cycles), three aliquots of each QC concentration were prepared in human plasma, stored at -80°C until completely frozen, and thawed unassisted at room temperature. Upon completion of thawing, the samples were refrozen at -80°C. The freeze-thaw cycle was then repeated for a total of two, five, and eight times respectively to execute three, six, and nine freeze-thaw cycles. Sample preparation, as stipulated in Section of Calibrator and Quality Control Sample Preparation with the exception of spiking with the standard working solutions, was then carried out to analyse the samples.</p></div><div id="sec014" class="sec"><h3 id="sec014title">Dilution factor</h3><p id="__p32" class="p p-first-last">In the quantification of patient samples, a few samples were found to exceed the maximum calibrated concentration of Exe (40.0 ng/mL). Dilution was carried out with blank human plasma by a factor of three before sample preparation. Actual concentrations of the patient samples were then back-calculated by multiplication of the quantified concentrations by three. Validation of the dilution procedure was carried out using spiked plasma samples of Exe at 50.0, 60.0, and 70.0 ng/mL in quadruplicates. No extrapolation of the calibration was performed to quantify Exe at concentrations above 40.0 ng/mL. </p></div><div id="sec015" class="sec sec-last"><h3 id="sec015title">Application in human plasma</h3><p id="__p33" class="p p-first">Human plasma samples were obtained from breast cancer patients with post-menopausal, hormone receptor positive advanced breast cancer enrolled in a pharmacokinetics/dynamics study at National University Hospital, Singapore. This clinical trial has been approved by the National Healthcare Group Domain Specific Review Board (DSRB), the Institutional Review Board (IRB) of National University Hospital. Written informed consent was obtained. It was documented in a DSRB-approved written informed consent form and signed by the subject or subject’s legally authorized representative. An oral dose of exemestane (25 mg) was administered daily, starting from day 1. Plasma samples were collected on day 29 before dosing, and 0.5, 1, 2, 4, 6, 8 and 24 hours after exemestane ingestion.</p><p id="__p34" class="p p-last">The samples were stored frozen at -80°C and thawed unassisted at room temperature prior to analysis. Sample preparative procedure was carried out as stipulated in Calibrator and Quality Control Sample Preparation, with the exception of spiking of the standard working solutions. Quantification of patient samples was derived and calculated using interpolation within the standard calibration curve. The area under the curve (AUC) in a plot of concentrations of Exe and its metabolites were calculated through non-compartmental analysis using pharmacokinetic software (WinNonlin 5.3.).</p></div></div><div id="sec016" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="sec016title">Results and Discussion</h2><div id="sec017" class="sec sec-first"><h3 id="sec017title">LC-MS/MS optimization</h3><p id="__p35" class="p p-first">Mass spectrometric parameters were optimised and the product ion mass spectra of each analyte under optimised conditions were as follows. Based on <a href="/pmc/articles/PMC4368747/figure/pone.0118553.g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone.0118553.g002" rid-ob="ob-pone.0118553.g002" co-legend-rid="lgnd_pone.0118553.g002"><span>Fig. 2</span></a>, mass transitions 297 &gt; 121 <em>m/z</em> and 300 &gt; 121 <em>m/z</em> were monitored for Exe (C<sub>20</sub>H<sub>24</sub>O<sub>2</sub>, molecular weight: 296.40) and Exe-d3 (C<sub>20</sub>H<sub>21</sub>O<sub>2</sub>D<sub>3</sub>, molecular weight: 299.43) respectively. Mass transitions 299 &gt; 135 <em>m/z</em> and 302 &gt; 135 <em>m/z</em> were monitored for 17DhExe (C<sub>20</sub>H<sub>26</sub>O<sub>2</sub>, molecular weight: 298.43) and 17DhExe-d3 (C<sub>20</sub>H<sub>23</sub>O<sub>2</sub>D<sub>3</sub>, molecular weight: 301.44) respectively. Mass transitions 475 &gt; 281 <em>m/z</em> and 478 &gt; 284 <em>m/z</em> were monitored for Exe17Oglu (C<sub>26</sub>H<sub>34</sub>O<sub>8</sub>, molecular weight: 474.54) and Exe17Oglu-d3 (C<sub>26</sub>H<sub>31</sub>O<sub>8</sub>D<sub>3</sub>, molecular weight: 477.56) respectively. The desolvation temperature was set at 500°C, the electrospray ionisation source 5500 V, and the optimised entrance potential 10 V. The optimised declustering potentials were set at 61 V for Exe, Exe-d3, 17DhExe, and 17DhExe-d3; and 81 V, for Exe17Oglu and Exe17Oglu-d3. The optimised collision energies were set at 33 V for Exe and Exe-d3; 29 V for 17DhExe and 17DhExe-d3; 23 V for Exe17Oglu and Exe17Oglu-d3. The optimised collision cell exit potentials were set at 8 V for Exe, Exe-d3, 17DhExe, and 17DhExe-d3; 14 V for Exe17Oglu and Exe17Oglu-d3 respectively.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone.0118553.g002" co-legend-rid="lgnd_pone.0118553.g002"><a href="/pmc/articles/PMC4368747/figure/pone.0118553.g002/" target="figure" rid-figpopup="pone.0118553.g002" rid-ob="ob-pone.0118553.g002"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140359724531840" class="figure"><a href="/pmc/articles/PMC4368747/figure/pone.0118553.g002/" target="figure" rid-figpopup="pone.0118553.g002" rid-ob="ob-pone.0118553.g002"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4368747_pone.0118553.g002.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is pone.0118553.g002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC4368747/bin/pone.0118553.g002.jpg"></a></div><div id="largeobj_idm140359724531840" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC4368747/figure/pone.0118553.g002/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_pone.0118553.g002"><div><a class="figpopup" href="/pmc/articles/PMC4368747/figure/pone.0118553.g002/" target="figure" rid-figpopup="pone.0118553.g002" rid-ob="ob-pone.0118553.g002">Fig 2</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Product ion mass spectra of (a) Exe (b) 17DhExe and (c) Exe17Oglu.</strong></div></div></div><p id="__p36">A total of three reversed-phase HPLC columns were investigated for chromatographic separation of analytes from endogeneous interferences and among analytes. BDS Hypersil C18 column was chosen as the final chromatographic column due to the successful baseline separation of analytes, reduced run-time and symmetrical chromatographic peaks achieved.</p><p id="__p37">Acetonitrile, methanol and acetonitrile—methanol mixture (70:30, v/v) were investigated as organic solvents for HPLC mobile phase. Acetonitrile was chosen as the final organic solvent due to the reduced run-time, baseline separation among the peaks of analytes and from the endogenous substances.</p><p id="__p38">Formic acid 0.1% and acetic acid 0.1% were investigated as aqueous solvents for HPLC mobile phase. Formic acid 0.1% was chosen as the final aqueous solvent due to the increased sensitivity and better peak shape achieved.</p><p id="__p39" class="p">Isocratic elution and gradient elution were investigated as programmes for chromatographic separation. Gradient elution was chosen as the final chromatographic programme due to the successful baseline separation of analytes, reduced endogeneous interference, and sharpened analyte peaks. In addition, Exe and 17DhExe are much more hydrophobic than Exe17Oglu. Hence, only the gradient elution can analyze Exe and its metabolites simultaneously within a short run time. The mobile phase was composed of 0.1% aqueous formic acid (Phase A) and acetonitrile (Phase B). The following gradient programme was used: 0.00–0.10 min: 25% B, 0.10–0.20 min: 25 → 62% B (linear), 0.20–1.60 min: 62% B, 1.60–1.65 min: 62 → 25% B (linear), 1.65–6.00 min: 25% B. The flow rate was set at 0.5 mL/min. The resulting chromatograms of 3 analytes at their low limit of quantitation are shown in <a href="/pmc/articles/PMC4368747/figure/pone.0118553.g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone.0118553.g003" rid-ob="ob-pone.0118553.g003" co-legend-rid="lgnd_pone.0118553.g003"><span>Fig. 3</span></a>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone.0118553.g003" co-legend-rid="lgnd_pone.0118553.g003"><a href="/pmc/articles/PMC4368747/figure/pone.0118553.g003/" target="figure" rid-figpopup="pone.0118553.g003" rid-ob="ob-pone.0118553.g003"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140359764669264" class="figure"><a href="/pmc/articles/PMC4368747/figure/pone.0118553.g003/" target="figure" rid-figpopup="pone.0118553.g003" rid-ob="ob-pone.0118553.g003"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4368747_pone.0118553.g003.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is pone.0118553.g003.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC4368747/bin/pone.0118553.g003.jpg"></a></div><div id="largeobj_idm140359764669264" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC4368747/figure/pone.0118553.g003/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_pone.0118553.g003"><div><a class="figpopup" href="/pmc/articles/PMC4368747/figure/pone.0118553.g003/" target="figure" rid-figpopup="pone.0118553.g003" rid-ob="ob-pone.0118553.g003">Fig 3</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Representative chromatograms of (a) Exe (b) 17DhExe and (c) Exe17Oglu at LLOQ and (a) Exe-d3, (b) DhExe-d3 as well as Exe17Oglu at 100 ng/mL as internal standards.</strong></div></div></div></div><div id="sec018" class="sec"><h3 id="sec018title">Extraction Protocol Optimisation</h3><p id="__p40" class="p p-first">Extraction and pre-concentration methods were optimised to improve the recovery and increase the sensitivity of the assay.</p><p id="__p41">Solid-phase extraction, liquid-liquid extraction and direct protein precipitation were carried out to investigate the optimal method for sample extraction.</p><p id="__p42">HLB, WCX, WAX and LC-CN solid phases were investigated for solid-phase extraction. All four solid phases were found to be unable to retain Exe17Oglu and thus unsuitable for sample extraction.</p><p id="__p43">Ethanol—ethyl acetate mixture (4:1, v/v) and methyl-tert-butyl-ether were investigated as organic solvents for liquid-liquid extraction. Both solvent systems were found to be unable to extract Exe17Oglu and thus unsuitable for sample extraction as well.</p><p id="__p44">Due to the different polarities of the analytes of interest, with Exe and 17DhExe being non-polar compounds, and Exe17Oglu being a highly polar substance, solid-phase extraction and liquid-liquid extraction methods were unable to extract all three analytes to a reasonable recovery. This may be due to the intrinsic nature of these extraction methods, which take advantage of the different polarities between compounds and interfering substances for separation from endogeneous interferences.</p><p id="__p45" class="p p-last">Acetonitrile in two volumes and three volumes were investigated as organic solvent for direct protein precipitation. Acetonitrile in three volumes was chosen as the final sample preparation method due to the sufficient sample clean-up and less matrix effect. Furthermore, no interfering peaks were observed in the chromatogram, which validated the use of acetonitrile in three volumes for protein precipitation.</p></div><div id="sec019" class="sec"><h3 id="sec019title">Method validation</h3><div id="sec020" class="sec sec-first"><p></p><h4 id="sec020title" class="inline">Selectivity, Carry-over and Linearity </h4><p id="__p46" class="p p-first">Selectivity for the analytes was shown by peak identification of analytes without interferences at their respective lower limits of quantification (LLOQ, 0.4 ng/mL, for Exe; and 0.2 ng/mL, both for 17DhExe and 17DhExe-17Oglu). A chromatogram of the standard plasma spiked with three analytes at the concentrations of LLOQ is shown in <a href="/pmc/articles/PMC4368747/figure/pone.0118553.g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone.0118553.g003" rid-ob="ob-pone.0118553.g003" co-legend-rid="lgnd_pone.0118553.g003"><span>Fig. 3</span></a>.</p><p id="__p47">No carry-over effect was shown as the injection of wash after that of plasma with highest spiked concentration showed no peaks.</p><p id="__p48" class="p p-last">Linearity of the calibration curves were shown by the high r<sup>2</sup> of &gt; 0.998, which implied a strong correlation between the peak area ratio and concentration of each analyte in their linear ranges of 0.4–40.0 ng/mL, for exemestane; and 0.2–15.0 ng/mL, for 17β-dihydroexemestane and 17β-dihydroexemestane-17-O-β-D-glucuronide.</p></div><div id="sec021" class="sec"><p></p><h4 id="sec021title" class="inline">Accuracy and Precision </h4><p id="__p49" class="p p-first">Results of intra-day and inter-day tests are shown in <a href="/pmc/articles/PMC4368747/table/pone.0118553.t001/" target="table" class="fig-table-link figpopup" rid-figpopup="pone.0118553.t001" rid-ob="ob-pone.0118553.t001" co-legend-rid=""><span>Table 1</span></a>. The precision (coefficient of variation) were ≤10.7%, 7.7% and 9.5% and the accuracies ranged from 88.8 to 103.1% for exemestane, 98.5 to 106.1% for 17β-dihydroexemestane and 92.0 to 103.2 for 17β-dihydroexemestane-17-O-β-D-glucuronide. Taken together, both intra-day and inter-day accuracy and precision were within 15%, as stipulated by the FDA guidelines.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="pone.0118553.t001"><h3>Table 1</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Intra-run and inter-run concentrations, accuracy and precision of QC samples for Exe, 17DhExe and Exe17Oglu.</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140359729190256" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="2" align="left" colspan="1">Analyte</th><th rowspan="2" align="left" colspan="1">Nominal Conc. (ng/mL)</th><th colspan="2" align="center" rowspan="1">
<span class="underline">Calculated Conc. (ng/mL)</span>
</th><th colspan="2" align="center" rowspan="1">
<sup>*</sup>
<span class="underline">Accuracy (%)</span>
</th><th colspan="2" align="center" rowspan="1">
<sup>
#
</sup>
<span class="underline">Precision (%)</span>
</th></tr><tr><th align="left" rowspan="1" colspan="1">Intra-day</th><th align="left" rowspan="1" colspan="1">Inter-day</th><th align="left" rowspan="1" colspan="1">Intra-day</th><th align="left" rowspan="1" colspan="1">Inter-day</th><th align="left" rowspan="1" colspan="1">Intra-day</th><th align="left" rowspan="1" colspan="1">Inter-day</th></tr></thead><tbody><tr><td rowspan="3" align="left" colspan="1">
<strong>Exe</strong>
</td><td align="center" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">2.94 ± 0.12</td><td align="left" rowspan="1" colspan="1">3.00 ± 0.26</td><td align="center" rowspan="1" colspan="1">97.9</td><td align="center" rowspan="1" colspan="1">100.1</td><td align="left" rowspan="1" colspan="1">4.02</td><td align="center" rowspan="1" colspan="1">8.81</td></tr><tr><td align="center" rowspan="1" colspan="1">7.5</td><td align="left" rowspan="1" colspan="1">6.66 ± 0.14</td><td align="left" rowspan="1" colspan="1">7.37 ± 0.79</td><td align="center" rowspan="1" colspan="1">88.8</td><td align="center" rowspan="1" colspan="1">98.3</td><td align="left" rowspan="1" colspan="1">2.13</td><td align="center" rowspan="1" colspan="1">10.7</td></tr><tr><td align="center" rowspan="1" colspan="1">25.0</td><td align="left" rowspan="1" colspan="1">23.72 ± 1.52</td><td align="left" rowspan="1" colspan="1">25.78 ± 2.41</td><td align="center" rowspan="1" colspan="1">94.9</td><td align="center" rowspan="1" colspan="1">103.1</td><td align="left" rowspan="1" colspan="1">6.41</td><td align="center" rowspan="1" colspan="1">9.34</td></tr><tr><td rowspan="3" align="left" colspan="1">
<strong>17DhExe</strong>
</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">1.57 ± 0.09</td><td align="left" rowspan="1" colspan="1">1.52 ± 0.10</td><td align="center" rowspan="1" colspan="1">104.5</td><td align="center" rowspan="1" colspan="1">101.3</td><td align="left" rowspan="1" colspan="1">5.69</td><td align="center" rowspan="1" colspan="1">6.22</td></tr><tr><td align="center" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">4.24 ± 0.31</td><td align="left" rowspan="1" colspan="1">4.09 ± 0.20</td><td align="center" rowspan="1" colspan="1">106.1</td><td align="center" rowspan="1" colspan="1">102.3</td><td align="left" rowspan="1" colspan="1">7.38</td><td align="center" rowspan="1" colspan="1">4.89</td></tr><tr><td align="center" rowspan="1" colspan="1">10.0</td><td align="left" rowspan="1" colspan="1">10.42 ± 0.75</td><td align="left" rowspan="1" colspan="1">9.85 ± 0.76</td><td align="center" rowspan="1" colspan="1">104.2</td><td align="center" rowspan="1" colspan="1">98.5</td><td align="left" rowspan="1" colspan="1">7.24</td><td align="center" rowspan="1" colspan="1">7.68</td></tr><tr><td rowspan="3" align="left" colspan="1">
<strong>Exe17Oglu</strong>
</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">1.49 ± 0.11</td><td align="left" rowspan="1" colspan="1">1.55 ± 0.08</td><td align="center" rowspan="1" colspan="1">99.3</td><td align="center" rowspan="1" colspan="1">103.2</td><td align="left" rowspan="1" colspan="1">7.38</td><td align="center" rowspan="1" colspan="1">5.58</td></tr><tr><td align="center" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">3.83 ± 0.37</td><td align="left" rowspan="1" colspan="1">4.06 ± 0.31</td><td align="center" rowspan="1" colspan="1">95.8</td><td align="center" rowspan="1" colspan="1">101.5</td><td align="left" rowspan="1" colspan="1">9.53</td><td align="center" rowspan="1" colspan="1">8.02</td></tr><tr><td align="center" rowspan="1" colspan="1">10.0</td><td align="left" rowspan="1" colspan="1">9.20 ± 0.49</td><td align="left" rowspan="1" colspan="1">9.72 ± 0.85</td><td align="center" rowspan="1" colspan="1">92.0</td><td align="center" rowspan="1" colspan="1">97.2</td><td align="left" rowspan="1" colspan="1">5.37</td><td align="center" rowspan="1" colspan="1">8.69</td></tr></tbody></table></div><div id="largeobj_idm140359729190256" class="largeobj-link align_right" style="display: none;"><a target="object" href="/pmc/articles/PMC4368747/table/pone.0118553.t001/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="t001fn001"><p id="__p50" class="p p-first-last">*Expressed as percentage of the mean value (n = 4) measured over the nominal value</p></div><div id="t001fn002"><p id="__p51" class="p p-first-last">
<sup>#</sup>Expressed as percentage of the standard deviation divided by the mean</p></div></div></div></div><div id="sec022" class="sec"><p></p><h4 id="sec022title" class="inline">Matrix Effect </h4><p id="__p52" class="p p-first">Matrix effect was demonstrated to be significant for Exe, 17DhExe, and Exe17Oglu. Ion suppression was significant, especially for Exe17Oglu. However, with the use of stable isotope-labelled IS for all three analytes, the relative matrix effect was demonstrated to be close to 100%, permitting correction of the matrix effect. Results of matrix effect tests are shown in <a href="/pmc/articles/PMC4368747/table/pone.0118553.t002/" target="table" class="fig-table-link figpopup" rid-figpopup="pone.0118553.t002" rid-ob="ob-pone.0118553.t002" co-legend-rid=""><span>Table 2</span></a>.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="pone.0118553.t002"><h3>Table 2</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Matrix Effect of QC Samples for Exe, 17DhExe and Exe17Oglu and their internal standards.</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140359761420320" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" rowspan="1" colspan="1">Analyte</th><th align="left" rowspan="1" colspan="1">Nominal Conc. (ng/mL)</th><th align="left" rowspan="1" colspan="1">
<sup>*</sup>Matrix Effect (%)</th><th align="left" rowspan="1" colspan="1">
<sup>*</sup>Matrix Effect of IS at 10 ng/mL (%)</th><th align="left" rowspan="1" colspan="1">
<sup>
#
</sup>Relative Matrix Effect (%)</th></tr></thead><tbody><tr><td rowspan="3" align="left" colspan="1">Exe</td><td align="center" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">64.2 ± 11.8</td><td align="left" rowspan="1" colspan="1">62.2 ± 7.18</td><td align="center" rowspan="1" colspan="1">103.2</td></tr><tr><td align="center" rowspan="1" colspan="1">7.5</td><td align="left" rowspan="1" colspan="1">62.3 ± 7.65</td><td align="left" rowspan="1" colspan="1">64.3 ± 9.03</td><td align="center" rowspan="1" colspan="1">96.9</td></tr><tr><td align="center" rowspan="1" colspan="1">25.0</td><td align="left" rowspan="1" colspan="1">61.4 ± 10.6</td><td align="left" rowspan="1" colspan="1">60.1 ± 4.35</td><td align="center" rowspan="1" colspan="1">102.2</td></tr><tr><td rowspan="3" align="left" colspan="1">17DhExe</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">53.3 ± 5.31</td><td align="left" rowspan="1" colspan="1">54.4 ± 9.83</td><td align="center" rowspan="1" colspan="1">98.0</td></tr><tr><td align="center" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">52.1 ± 3.13</td><td align="left" rowspan="1" colspan="1">53.0 ±8.76</td><td align="center" rowspan="1" colspan="1">98.3</td></tr><tr><td align="center" rowspan="1" colspan="1">10.0</td><td align="left" rowspan="1" colspan="1">53.4 ± 4.41</td><td align="left" rowspan="1" colspan="1">55.3 ± 6.54</td><td align="center" rowspan="1" colspan="1">96.6</td></tr><tr><td rowspan="3" align="left" colspan="1">Exe17Oglu</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">33.1 ± 4.88</td><td align="left" rowspan="1" colspan="1">31.2 ± 5.02</td><td align="center" rowspan="1" colspan="1">106.1</td></tr><tr><td align="center" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">34.1 ± 3.16</td><td align="left" rowspan="1" colspan="1">35.0 ± 3.69</td><td align="center" rowspan="1" colspan="1">97.4</td></tr><tr><td align="center" rowspan="1" colspan="1">10.0</td><td align="left" rowspan="1" colspan="1">35.3 ± 2.65</td><td align="left" rowspan="1" colspan="1">35.2 ± 2.84</td><td align="center" rowspan="1" colspan="1">100.3</td></tr></tbody></table></div><div id="largeobj_idm140359761420320" class="largeobj-link align_right" style="display: none;"><a target="object" href="/pmc/articles/PMC4368747/table/pone.0118553.t002/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="t002fn001"><p id="__p53" class="p p-first-last">*Expressed as average percentage (n = 4) of peak area of analyte in matrix-based tube with that in reference tube</p></div><div id="t002fn002"><p id="__p54" class="p p-first-last">
<sup>#</sup>Expressed as ratio of matrix effect on compound to that of IS</p></div></div></div></div><div id="sec023" class="sec"><p></p><h4 id="sec023title" class="inline">Recovery </h4><p id="__p55" class="p p-first">The relative recoveries of Exe, Exe-d3, 17DhExe, and 17DhExe-d3 were demonstrated to be greater than 98%. This showed that the extraction protocol was efficient and complete for these four compounds. Even though the relative recoveries of Exe17Oglu and Exe17Oglu-d3 were found to be about 85%, the recoveries of Exe17Oglu and its IS were consistent and similar, allowing adjustment of the low recovery and fulfilling the FDA validation guidelines. Results of recovery tests are shown in <a href="/pmc/articles/PMC4368747/table/pone.0118553.t003/" target="table" class="fig-table-link figpopup" rid-figpopup="pone.0118553.t003" rid-ob="ob-pone.0118553.t003" co-legend-rid=""><span>Table 3</span></a>.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="pone.0118553.t003"><h3>Table 3</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Recovery of QC Samples for Exe, Exe-d3, 17DhExe, 17DhExe-d3, Exe17Oglu, and Exe17Oglu-d3.</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140359728481840" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" rowspan="1" colspan="1">Compound</th><th align="left" rowspan="1" colspan="1">Nominal Concentration (ng/mL)</th><th align="left" rowspan="1" colspan="1">
<sup>*</sup>Recovery (%)</th></tr></thead><tbody><tr><td rowspan="3" align="left" colspan="1">Exe</td><td align="center" rowspan="1" colspan="1">3.0</td><td align="center" rowspan="1" colspan="1">109.5</td></tr><tr><td align="center" rowspan="1" colspan="1">7.5</td><td align="center" rowspan="1" colspan="1">98.3</td></tr><tr><td align="center" rowspan="1" colspan="1">25.0</td><td align="center" rowspan="1" colspan="1">109.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Exe-d3</td><td align="center" rowspan="1" colspan="1">10.0</td><td align="center" rowspan="1" colspan="1">107.9</td></tr><tr><td rowspan="3" align="left" colspan="1">17DhExe</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">106.8</td></tr><tr><td align="center" rowspan="1" colspan="1">4.0</td><td align="center" rowspan="1" colspan="1">102.8</td></tr><tr><td align="center" rowspan="1" colspan="1">10.0</td><td align="center" rowspan="1" colspan="1">108.3</td></tr><tr><td align="left" rowspan="1" colspan="1">17DhExe-d3</td><td align="center" rowspan="1" colspan="1">10.0</td><td align="center" rowspan="1" colspan="1">109.4</td></tr><tr><td rowspan="3" align="left" colspan="1">Exe17Oglu</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">86.4</td></tr><tr><td align="center" rowspan="1" colspan="1">4.0</td><td align="center" rowspan="1" colspan="1">85.3</td></tr><tr><td align="center" rowspan="1" colspan="1">10.0</td><td align="center" rowspan="1" colspan="1">84.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Exe17Oglu-d3</td><td align="center" rowspan="1" colspan="1">10.0</td><td align="center" rowspan="1" colspan="1">86.0</td></tr></tbody></table></div><div id="largeobj_idm140359728481840" class="largeobj-link align_right" style="display: none;"><a target="object" href="/pmc/articles/PMC4368747/table/pone.0118553.t003/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="t003fn001"><p id="__p56" class="p p-first-last">*Expressed as mean percentage (n = 4) of peak area of analyte in the tube spiked before extraction to that in the tube spiked after extraction</p></div></div></div></div><div id="sec024" class="sec"><p></p><h4 id="sec024title" class="inline">Stability </h4><p id="__p57" class="p p-first">Stabilities of Exe, 17DhExe, and Exe17Oglu were demonstrated to be within ± 15% of nominal concentrations. This indicated that the analytes of interest was stable in human plasma during short-term bench-top storage and freeze-thaw cycles. Results of stability tests are shown in <a href="/pmc/articles/PMC4368747/table/pone.0118553.t004/" target="table" class="fig-table-link figpopup" rid-figpopup="pone.0118553.t004" rid-ob="ob-pone.0118553.t004" co-legend-rid=""><span>Table 4</span></a>.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="pone.0118553.t004"><h3>Table 4</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Short-term and freeze-thaw stability of QC samples of Exe, 17DhExe and Exe17Oglu.</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140359801200720" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"></th><th colspan="6" align="center" rowspan="1">Stability<sup>*</sup>
</th></tr><tr><th rowspan="2" align="left" colspan="1">Analyte</th><th align="left" rowspan="1" colspan="1">Nominal Conc.</th><th colspan="3" align="center" rowspan="1">Short-term (hours)</th><th colspan="3" align="center" rowspan="1">Freeze-thaw (cycles)</th></tr><tr><th align="left" rowspan="1" colspan="1">ng/mL</th><th align="left" rowspan="1" colspan="1">4</th><th align="left" rowspan="1" colspan="1">8</th><th align="left" rowspan="1" colspan="1">24</th><th align="left" rowspan="1" colspan="1">3</th><th align="left" rowspan="1" colspan="1">6</th><th align="left" rowspan="1" colspan="1">9</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1">3.0</td><td align="center" rowspan="1" colspan="1">106.8</td><td align="center" rowspan="1" colspan="1">108.7</td><td align="center" rowspan="1" colspan="1">88.2</td><td align="center" rowspan="1" colspan="1">103.8</td><td align="center" rowspan="1" colspan="1">113.9</td><td align="center" rowspan="1" colspan="1">112.7</td></tr><tr><td rowspan="3" align="left" colspan="1">Exe</td><td align="center" rowspan="1" colspan="1">7.5</td><td align="center" rowspan="1" colspan="1">114.3</td><td align="center" rowspan="1" colspan="1">108.8</td><td align="center" rowspan="1" colspan="1">105.1</td><td align="center" rowspan="1" colspan="1">114.0</td><td align="center" rowspan="1" colspan="1">112.4</td><td align="center" rowspan="1" colspan="1">110.9</td></tr><tr><td align="center" rowspan="1" colspan="1">25.0</td><td align="center" rowspan="1" colspan="1">112.8</td><td align="center" rowspan="1" colspan="1">109.6</td><td align="center" rowspan="1" colspan="1">95.1</td><td align="center" rowspan="1" colspan="1">109.6</td><td align="center" rowspan="1" colspan="1">112.0</td><td align="center" rowspan="1" colspan="1">113.1</td></tr><tr><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">111.1</td><td align="center" rowspan="1" colspan="1">112.0</td><td align="center" rowspan="1" colspan="1">109.6</td><td align="center" rowspan="1" colspan="1">106.0</td><td align="center" rowspan="1" colspan="1">108.0</td><td align="center" rowspan="1" colspan="1">110.7</td></tr><tr><td rowspan="3" align="left" colspan="1">17DhExe</td><td align="center" rowspan="1" colspan="1">4.0</td><td align="center" rowspan="1" colspan="1">111.8</td><td align="center" rowspan="1" colspan="1">109.6</td><td align="center" rowspan="1" colspan="1">111.8</td><td align="center" rowspan="1" colspan="1">108.7</td><td align="center" rowspan="1" colspan="1">110.1</td><td align="center" rowspan="1" colspan="1">112.5</td></tr><tr><td align="center" rowspan="1" colspan="1">10.0</td><td align="center" rowspan="1" colspan="1">109.7</td><td align="center" rowspan="1" colspan="1">112.0</td><td align="center" rowspan="1" colspan="1">112.7</td><td align="center" rowspan="1" colspan="1">108.0</td><td align="center" rowspan="1" colspan="1">109.7</td><td align="center" rowspan="1" colspan="1">104.7</td></tr><tr><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">100.7</td><td align="center" rowspan="1" colspan="1">106.0</td><td align="center" rowspan="1" colspan="1">95.6</td><td align="center" rowspan="1" colspan="1">94.9</td><td align="center" rowspan="1" colspan="1">100.2</td><td align="center" rowspan="1" colspan="1">107.6</td></tr><tr><td rowspan="2" align="left" colspan="1">Exe17Oglu</td><td align="center" rowspan="1" colspan="1">4.0</td><td align="center" rowspan="1" colspan="1">101.7</td><td align="center" rowspan="1" colspan="1">105.7</td><td align="center" rowspan="1" colspan="1">103.5</td><td align="center" rowspan="1" colspan="1">96.6</td><td align="center" rowspan="1" colspan="1">107.3</td><td align="center" rowspan="1" colspan="1">110.7</td></tr><tr><td align="center" rowspan="1" colspan="1">10.0</td><td align="center" rowspan="1" colspan="1">107.7</td><td align="center" rowspan="1" colspan="1">109.7</td><td align="center" rowspan="1" colspan="1">107.3</td><td align="center" rowspan="1" colspan="1">106.4</td><td align="center" rowspan="1" colspan="1">101.9</td><td align="center" rowspan="1" colspan="1">110.0</td></tr></tbody></table></div><div id="largeobj_idm140359801200720" class="largeobj-link align_right" style="display: none;"><a target="object" href="/pmc/articles/PMC4368747/table/pone.0118553.t004/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="t004fn001"><p id="__p58" class="p p-first-last">*Expressed as mean percentage (n = 3) of quantified concentration to nominal concentration</p></div></div></div></div><div id="sec025" class="sec sec-last"><p></p><h4 id="sec025title" class="inline">Dilution Factor </h4><p id="__p59" class="p p-first">Due to the presence of patient samples which exceed the maximum calibrated concentration of Exe (40.0 ng/mL), dilution was carried out with blank human plasma by a factor of three before sample preparation. Accuracy and precision of the dilution procedure prior to sample preparation were within 10%, thus ensuring reliability of the procedure. Results of accuracy and precision of the dilution procedure are shown in <a href="/pmc/articles/PMC4368747/table/pone.0118553.t005/" target="table" class="fig-table-link figpopup" rid-figpopup="pone.0118553.t005" rid-ob="ob-pone.0118553.t005" co-legend-rid=""><span>Table 5</span></a>.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="pone.0118553.t005"><h3>Table 5</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Accuracy and Precision of Dilution Procedure for Exe.</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140359724248928" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" rowspan="1" colspan="1">Nominal Concentration (ng/mL)</th><th align="left" rowspan="1" colspan="1">Dilution Factor</th><th align="left" rowspan="1" colspan="1">Quantified Concentration(Mean ± S.D., ng/mL)</th><th align="left" rowspan="1" colspan="1">
<sup>*</sup>Accuracy (%)</th><th align="left" rowspan="1" colspan="1">
<sup>
#
</sup>Precision (%)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">50.0</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">46.90 ± 1.86</td><td align="center" rowspan="1" colspan="1">93.8</td><td align="center" rowspan="1" colspan="1">3.97</td></tr><tr><td align="center" rowspan="1" colspan="1">60.0</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">58.43 ± 1.02</td><td align="center" rowspan="1" colspan="1">97.4</td><td align="center" rowspan="1" colspan="1">1.75</td></tr><tr><td align="center" rowspan="1" colspan="1">70.0</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">73.88 ± 2.28</td><td align="center" rowspan="1" colspan="1">105.5</td><td align="center" rowspan="1" colspan="1">3.09</td></tr></tbody></table></div><div id="largeobj_idm140359724248928" class="largeobj-link align_right" style="display: none;"><a target="object" href="/pmc/articles/PMC4368747/table/pone.0118553.t005/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="t005fn001"><p id="__p60" class="p p-first-last">*Expressed as mean percentage (n = 4) of the mean value measured over the nominal value</p></div><div id="t005fn002"><p id="__p61" class="p p-first-last">
<sup>#</sup>Expressed as percentage of the standard deviation divided by the mean</p></div></div></div></div></div><div id="sec026" class="sec sec-last"><h3 id="sec026title">Application of Validated LC-MS/MS Method</h3><p id="__p62" class="p p-first">The developed method for the simultaneous quantification of Exe and its metabolites, 17DhExe, and Exe17Oglu was successfully applied in a pharmacokinetics/dynamics study, in which all the plasma samples taken from one typical patient were quantified for the concentrations of Exe, 17DhExe, and Exe17Oglu over 24 hours after exemestane ingestion at dose of 25 mg. Pharmacokinetic profiles were plotted and are shown in <a href="/pmc/articles/PMC4368747/figure/pone.0118553.g004/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone.0118553.g004" rid-ob="ob-pone.0118553.g004" co-legend-rid="lgnd_pone.0118553.g004"><span>Fig. 4</span></a> in which the time-concentration profiles of Exe, 17DhExe and Exe17Oglu were well described with 24 hours. The maximum concentrations of Exe, 17DhExe and Exe17Oglu were observed as 38.5, 3.6 and 1.5 ng/mL respectively at 2 hours after exemestane ingestion. The AUC calculated using WinNonlin software with non-compartmental analysis were 129.6, 24.2 and 15.7 ng/mL for Exe, 17DhExe, and Exe17Oglu respectively.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone.0118553.g004" co-legend-rid="lgnd_pone.0118553.g004"><a href="/pmc/articles/PMC4368747/figure/pone.0118553.g004/" target="figure" rid-figpopup="pone.0118553.g004" rid-ob="ob-pone.0118553.g004"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140359726960160" class="figure"><a href="/pmc/articles/PMC4368747/figure/pone.0118553.g004/" target="figure" rid-figpopup="pone.0118553.g004" rid-ob="ob-pone.0118553.g004"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=4368747_pone.0118553.g004.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is pone.0118553.g004.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC4368747/bin/pone.0118553.g004.jpg"></a></div><div id="largeobj_idm140359726960160" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC4368747/figure/pone.0118553.g004/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_pone.0118553.g004"><div><a class="figpopup" href="/pmc/articles/PMC4368747/figure/pone.0118553.g004/" target="figure" rid-figpopup="pone.0118553.g004" rid-ob="ob-pone.0118553.g004">Fig 4</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Mean concentrations of a) Exe (b) 17DhExe and (c) Exe17Oglu in plasma samples of one representative breast cancer patient.</strong></div></div></div></div></div><div id="sec027" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="sec027title">Conclusions</h2><p id="__p63" class="p p-first-last">A simple, novel and specific LC-MS/MS assay for the quantification of Exe and its two main metabolites was developed and fully validated according to the FDA guidelines. This method offers a significant advantage over previously reported methods due to its ability to quantify Exe17Oglu as well. Excellent linearity was demonstrated within the ranges of 1.0–40.0ng/mL for Exe and 0.5–15.0ng/mL for 17DhExe and Exe17Oglu. Accuracy and precision (CV) were well within FDA guidelines of &lt; 15%. The method was also successfully utilised for the quantification of Exe and its two main metabolites in human plasma in a pharmacokinetics/dynamics study. For a representative patient, 20.7% of exemestane in plasma was converted into 17β-dihydroexemestane and 29.0% of 17β-dihydroexemestane was inactivated as 17β-dihydroexemestane-17-O-β-D-glucuronide 24 hours after ingestion of exemestane, suggesting that altered 17-dihydroexemestane glucuronidation may play an important role in determining effect of exemestane against breast cancer cells due to genetic difference of UGT2B17 among breast cancer patients.</p></div><div id="idm140359726956656" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140359726956656title">Acknowledgments</h2><div class="sec"><p id="__p64">We would like to express our deep appreciation to Ms. Khoo Yok Moi for her meticulous guidance on solid-phase extraction optimization, Dr. Fan Lu for her thorough assistance on the use of WinNonlin software and Ms. Luo Wenxia for her wonderful help through this project.</p></div></div><div id="idm140359727670512" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140359727670512title">Funding Statement</h2><p>The study was sponsored by the National Research Foundation of Singapore (Experimental Therapeutics Program) and the National Medical Research Council of Singapore (NMRC/CSA/021/2010 and NMRC/NIG/MH95:03/1-36/2012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></div><div id="idm140359727667536" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140359727667536title">Data Availability</h2><p id="__p4">All relevant data are within the paper.</p></div><div id="idm140359726955744" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140359726955744title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref001">1. <span class="mixed-citation">
Teo MC, Soo KC. <span class="ref-title">Cancer Trends and Incidences in Singapore</span>. <span class="ref-journal">Jpn J Clin Oncol</span>., 2013.  (<span class="ref-iss">43</span>):219–24. 10.1093/jjco/hys230
 [<a href="/pubmed/23303840" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1093%2Fjjco%2Fhys230" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Jpn+J+Clin+Oncol&amp;title=Cancer+Trends+and+Incidences+in+Singapore&amp;author=MC+Teo&amp;author=KC+Soo&amp;issue=43&amp;publication_year=2013&amp;pages=219-24&amp;pmid=23303840&amp;doi=10.1093/jjco/hys230&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref002">2. <span class="mixed-citation">
Kim SH, Park IH, Lee H, Lee KS, Nam BH, Ro J. <span class="ref-title">Efficacy of exemestane after nonsteroidal aromatase inhibitor use in metastatic breast cancer patients</span>. <span class="ref-journal">Asian Pac J Cancer Prev</span>., 2012; <span class="ref-vol">13</span>(<span class="ref-iss">3</span>): 979–983.
 [<a href="/pubmed/22631683" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Asian+Pac+J+Cancer+Prev&amp;title=Efficacy+of+exemestane+after+nonsteroidal+aromatase+inhibitor+use+in+metastatic+breast+cancer+patients&amp;author=SH+Kim&amp;author=IH+Park&amp;author=H+Lee&amp;author=KS+Lee&amp;author=BH+Nam&amp;volume=13&amp;issue=3&amp;publication_year=2012&amp;pages=979-983&amp;pmid=22631683&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref003">3. <span class="mixed-citation">
Zhang Y, Simondsen K, Kolesar JM. <span class="ref-title">Exemestane for primary prevention of breast cancer in postmenopausal women</span>. <span class="ref-journal">Am J Health Syst Pharm</span>, 2012; <span class="ref-vol">69</span>(<span class="ref-iss">16</span>): 1384–1388. 10.2146/ajhp110585
 [<a href="/pubmed/22855103" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.2146%2Fajhp110585" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Health+Syst+Pharm&amp;title=Exemestane+for+primary+prevention+of+breast+cancer+in+postmenopausal+women&amp;author=Y+Zhang&amp;author=K+Simondsen&amp;author=JM+Kolesar&amp;volume=69&amp;issue=16&amp;publication_year=2012&amp;pages=1384-1388&amp;pmid=22855103&amp;doi=10.2146/ajhp110585&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref004">4. <span class="mixed-citation">
Takashima S, Kiyoto S, Takahashi M, Hara F, Takabatake D, Aogi K, et al.
<span class="ref-title">Examination of the use of Exemestane in patients with metastatic breast cancer</span>. <span class="ref-journal">Breast Cancer</span>, 2011. 
<span class="ref-vol">18</span>(<span class="ref-iss">3</span>): 189–194. 10.1007/s12282-011-0258-5
 [<a href="/pubmed/21437667" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1007%2Fs12282-011-0258-5" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer&amp;title=Examination+of+the+use+of+Exemestane+in+patients+with+metastatic+breast+cancer&amp;author=S+Takashima&amp;author=S+Kiyoto&amp;author=M+Takahashi&amp;author=F+Hara&amp;author=D+Takabatake&amp;volume=18&amp;issue=3&amp;publication_year=2011&amp;pages=189-194&amp;pmid=21437667&amp;doi=10.1007/s12282-011-0258-5&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref005">5. <span class="mixed-citation">
Litton JK, Bevers TB, Arun BK. <span class="ref-title">Exemestane in the prevention setting</span>. <span class="ref-journal">Ther Adv Med Oncol</span>., 2012; <span class="ref-vol">4</span>(<span class="ref-iss">3</span>): 107–112. 10.1177/1758834012438214
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3349074/">PMC free article</a>]</span> [<a href="/pubmed/22590484" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1177%2F1758834012438214" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ther+Adv+Med+Oncol&amp;title=Exemestane+in+the+prevention+setting&amp;author=JK+Litton&amp;author=TB+Bevers&amp;author=BK+Arun&amp;volume=4&amp;issue=3&amp;publication_year=2012&amp;pages=107-112&amp;pmid=22590484&amp;doi=10.1177/1758834012438214&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref006">6. <span class="mixed-citation">
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, et al.
<span class="ref-title">American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor—Positive Breast Cancer: Status Report 2002</span>. <span class="ref-journal">Journal of Clinical Oncology</span>, 2002; <span class="ref-vol">20</span>(<span class="ref-iss">15</span>): 3317–3327.
 [<a href="/pubmed/12149306" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Oncology&amp;title=American+Society+of+Clinical+Oncology+Technology+Assessment+on+the+Use+of+Aromatase+Inhibitors+as+Adjuvant+Therapy+for+Women+With+Hormone+Receptor—Positive+Breast+Cancer:+Status+Report+2002&amp;author=EP+Winer&amp;author=C+Hudis&amp;author=HJ+Burstein&amp;author=RT+Chlebowski&amp;author=JN+Ingle&amp;volume=20&amp;issue=15&amp;publication_year=2002&amp;pages=3317-3327&amp;pmid=12149306&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref007">7. <span class="mixed-citation">
Lønning PE, Geisler J. <span class="ref-title">Experience with Exemestane in the Treatment of Early and Advanced Breast Cancer</span>. <span class="ref-journal">Expert Opin. Drug Metab. Toxicol.</span>, 2008; <span class="ref-vol">4</span>(<span class="ref-iss">7</span>):987–997. 10.1517/17425255.4.7.987
 [<a href="/pubmed/18624685" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1517%2F17425255.4.7.987" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Opin.+Drug+Metab.+Toxicol.&amp;title=Experience+with+Exemestane+in+the+Treatment+of+Early+and+Advanced+Breast+Cancer&amp;author=PE+Lønning&amp;author=J+Geisler&amp;volume=4&amp;issue=7&amp;publication_year=2008&amp;pages=987-997&amp;pmid=18624685&amp;doi=10.1517/17425255.4.7.987&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref008">8. <span class="mixed-citation">
Kittaneh M, Glück S. <span class="ref-title">Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women</span>. <span class="ref-journal">Breast Cancer, Breast Cancer (Auckl)</span>, 2011; <span class="ref-vol">5</span>:209–226. 10.4137/BCBCR.S6234
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3201097/">PMC free article</a>]</span> [<a href="/pubmed/22084574" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.4137%2FBCBCR.S6234" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer,+Breast+Cancer+(Auckl)&amp;title=Exemestane+in+the+Adjuvant+Treatment+of+Breast+Cancer+in+Postmenopausal+Women&amp;author=M+Kittaneh&amp;author=S+Glück&amp;volume=5&amp;publication_year=2011&amp;pages=209-226&amp;pmid=22084574&amp;doi=10.4137/BCBCR.S6234&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref009">9. <span class="mixed-citation">
Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI. <span class="ref-title">Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review</span>. <span class="ref-journal">Cancer Treatment Reviews</span>, 2008; <span class="ref-vol">34</span>(<span class="ref-iss">2</span>):157–174. 10.1016/j.ctrv.2007.11.001
 [<a href="/pubmed/18164821" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.ctrv.2007.11.001" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Treatment+Reviews&amp;title=Aromatase+inhibitors+in+adjuvant+therapy+for+hormone+receptor+positive+breast+cancer:+A+systematic+review&amp;author=A+Eisen&amp;author=M+Trudeau&amp;author=W+Shelley&amp;author=H+Messersmith&amp;author=KI+Pritchard&amp;volume=34&amp;issue=2&amp;publication_year=2008&amp;pages=157-174&amp;pmid=18164821&amp;doi=10.1016/j.ctrv.2007.11.001&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref010">10. <span class="mixed-citation">
Winters L1, Habin K, Gallagher J. <span class="ref-title">Aromatase inhibitors and musculoskeletal pain in patients with breast cancer</span>. <span class="ref-journal">Clin J Oncol Nurs</span>. 2007;<span class="ref-vol">11</span>(<span class="ref-iss">3</span>):433–9.
 [<a href="/pubmed/17623627" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+J+Oncol+Nurs&amp;title=Aromatase+inhibitors+and+musculoskeletal+pain+in+patients+with+breast+cancer&amp;author=L1+Winters&amp;author=K+Habin&amp;author=J+Gallagher&amp;volume=11&amp;issue=3&amp;publication_year=2007&amp;pages=433-9&amp;pmid=17623627&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref011">11. <span class="mixed-citation">
Herold CI1, Blackwell KL. <span class="ref-title">Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease</span>. <span class="ref-journal">Clin Breast Cancer</span>. 2008; <span class="ref-vol">8</span>(<span class="ref-iss">1</span>):50–64. 10.3816/CBC.2008.n.003
 [<a href="/pubmed/18501059" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.3816%2FCBC.2008.n.003" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Breast+Cancer&amp;title=Aromatase+inhibitors+for+breast+cancer:+proven+efficacy+across+the+spectrum+of+disease&amp;author=CI1+Herold&amp;author=KL+Blackwell&amp;volume=8&amp;issue=1&amp;publication_year=2008&amp;pages=50-64&amp;pmid=18501059&amp;doi=10.3816/CBC.2008.n.003&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref012">12. <span class="mixed-citation">
Tomao F1, Spinelli G, Vici P, Pisanelli GC, Cascialli G, Frati L, et al.
<span class="ref-title">Current role and safety profile of aromatase inhibitors in early breast cancer</span>. <span class="ref-journal">Expert Rev Anticancer Ther</span>. 2011;<span class="ref-vol">11</span>(<span class="ref-iss">8</span>):1253–63. 10.1586/era.11.96
 [<a href="/pubmed/21916579" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1586%2Fera.11.96" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Rev+Anticancer+Ther&amp;title=Current+role+and+safety+profile+of+aromatase+inhibitors+in+early+breast+cancer&amp;author=F1+Tomao&amp;author=G+Spinelli&amp;author=P+Vici&amp;author=GC+Pisanelli&amp;author=G+Cascialli&amp;volume=11&amp;issue=8&amp;publication_year=2011&amp;pages=1253-63&amp;pmid=21916579&amp;doi=10.1586/era.11.96&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref013">13. <span class="mixed-citation">
Van Asten K1, Neven P, Lintermans A, Wildiers H, Paridaens R. <span class="ref-title">Aromatase inhibitors in the breast cancer clinic: focus on exemestane</span>. <span class="ref-journal">Endocr Relat Cancer</span>. 2014; <span class="ref-vol">21</span>(<span class="ref-iss">1</span>):R31–49. 10.1530/ERC-13-0269
 [<a href="/pubmed/24434719" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1530%2FERC-13-0269" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Endocr+Relat+Cancer&amp;title=Aromatase+inhibitors+in+the+breast+cancer+clinic:+focus+on+exemestane&amp;author=K1+Van+Asten&amp;author=P+Neven&amp;author=A+Lintermans&amp;author=H+Wildiers&amp;author=R+Paridaens&amp;volume=21&amp;issue=1&amp;publication_year=2014&amp;pages=R31-49&amp;pmid=24434719&amp;doi=10.1530/ERC-13-0269&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref014">14. <span class="mixed-citation">
Cavalcantia Gde A, Garridoa BC, Leala FD. <span class="ref-title">Detection of new urinary exemestane metabolites by gas chromatography coupled to mass spectrometry</span>. <span class="ref-journal">Steroids</span>, 2011; <span class="ref-vol">76</span>:1010–1015. 10.1016/j.steroids.2011.04.001
 [<a href="/pubmed/21530565" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.steroids.2011.04.001" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Steroids&amp;title=Detection+of+new+urinary+exemestane+metabolites+by+gas+chromatography+coupled+to+mass+spectrometry&amp;author=A+Cavalcantia+Gde&amp;author=BC+Garridoa&amp;author=FD+Leala&amp;volume=76&amp;publication_year=2011&amp;pages=1010-1015&amp;pmid=21530565&amp;doi=10.1016/j.steroids.2011.04.001&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref015">15. <span class="mixed-citation">
Kamdem LK, Flockhart DA, Desta Z. <span class="ref-title">In Vitro Cytochrome P450-Mediated Metabolism of Exemestane</span>. <span class="ref-journal">Drug Metabolism and Disposition</span>, 2011; <span class="ref-vol">39</span>(<span class="ref-iss">1</span>):98–105. 10.1124/dmd.110.032276
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3014267/">PMC free article</a>]</span> [<a href="/pubmed/20876785" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1124%2Fdmd.110.032276" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+Metabolism+and+Disposition&amp;title=In+Vitro+Cytochrome+P450-Mediated+Metabolism+of+Exemestane&amp;author=LK+Kamdem&amp;author=DA+Flockhart&amp;author=Z+Desta&amp;volume=39&amp;issue=1&amp;publication_year=2011&amp;pages=98-105&amp;pmid=20876785&amp;doi=10.1124/dmd.110.032276&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref016">16. <span class="mixed-citation">
Sun D, Chen G, Dellinger RW, Sharma AK, Lazarus P. <span class="ref-title">Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics</span>. <span class="ref-journal">Pharmacogenetics and Genomics</span>, 2010; <span class="ref-vol">20</span>(<span class="ref-iss">10</span>):575–585. 10.1097/FPC.0b013e32833b04af
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3076703/">PMC free article</a>]</span> [<a href="/pubmed/20697310" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1097%2FFPC.0b013e32833b04af" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenetics+and+Genomics&amp;title=Characterization+of+17-dihydroexemestane+glucuronidation:+potential+role+of+the+UGT2B17+deletion+in+exemestane+pharmacogenetics&amp;author=D+Sun&amp;author=G+Chen&amp;author=RW+Dellinger&amp;author=AK+Sharma&amp;author=P+Lazarus&amp;volume=20&amp;issue=10&amp;publication_year=2010&amp;pages=575-585&amp;pmid=20697310&amp;doi=10.1097/FPC.0b013e32833b04af&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref017">17. <span class="mixed-citation">
Wong NS1, Seah EZh, Wang LZ, Yeo WL, Yap HL, Chuah B, et al.
<span class="ref-title">Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer</span>. <span class="ref-journal">Pharmacogenetics and Genomics</span>, 2011; <span class="ref-vol">21</span>(<span class="ref-iss">11</span>):760–768. 10.1097/FPC.0b013e32834a8639
 [<a href="/pubmed/21849928" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1097%2FFPC.0b013e32834a8639" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenetics+and+Genomics&amp;title=Impact+of+UDP-gluconoryltransferase+2B17+genotype+on+vorinostat+metabolism+and+clinical+outcomes+in+Asian+women+with+breast+cancer&amp;author=NS1+Wong&amp;author=EZh+Seah&amp;author=LZ+Wang&amp;author=WL+Yeo&amp;author=HL+Yap&amp;volume=21&amp;issue=11&amp;publication_year=2011&amp;pages=760-768&amp;pmid=21849928&amp;doi=10.1097/FPC.0b013e32834a8639&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref018">18. <span class="mixed-citation">
Breda M, Pianezzola E, Benedetti MS. <span class="ref-title">Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection</span>. <span class="ref-journal">J Chromatogr</span>., 1993; <span class="ref-vol">620</span>(<span class="ref-iss">2</span>):225–31.
 [<a href="/pubmed/8300790" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Chromatogr&amp;title=Determination+of+exemestane,+a+new+aromatase+inhibitor,+in+plasma+by+high-performance+liquid+chromatography+with+ultraviolet+detection&amp;author=M+Breda&amp;author=E+Pianezzola&amp;author=MS+Benedetti&amp;volume=620&amp;issue=2&amp;publication_year=1993&amp;pages=225-31&amp;pmid=8300790&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref019">19. <span class="mixed-citation">
Corona G, Elia C, Casetta B, Diana C, Rosalen S, Bari M, et al.
<span class="ref-title">A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma</span>. <span class="ref-journal">Journal of Mass Spectrometry</span>, 2009; <span class="ref-vol">44</span>(<span class="ref-iss">6</span>):920–928. 10.1002/jms.1566
 [<a href="/pubmed/19214962" target="pmc_ext" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1002%2Fjms.1566" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Mass+Spectrometry&amp;title=A+liquid+chromatography-tandem+mass+spectrometry+method+for+the+simultaneous+determination+of+exemestane+and+its+metabolite+17-dihydroexemestane+in+human+plasma&amp;author=G+Corona&amp;author=C+Elia&amp;author=B+Casetta&amp;author=C+Diana&amp;author=S+Rosalen&amp;volume=44&amp;issue=6&amp;publication_year=2009&amp;pages=920-928&amp;pmid=19214962&amp;doi=10.1002/jms.1566&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0118553.ref020">20. <span class="mixed-citation">Guidance for Industry Bioanalytical Method Validation. Available: <a href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf</a>
</span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2" style=""><li><a href="#ui-ncbiinpagenav-heading-3">Associated Data</a></li><li><a href="#idm140359761133280title">Abstract</a></li><li><a href="#sec001title">Introduction</a></li><li><a href="#sec002title">Experimental</a></li><li><a href="#sec016title">Results and Discussion</a></li><li><a href="#sec027title">Conclusions</a></li><li><a href="#idm140359726956656title">Acknowledgments</a></li><li><a href="#idm140359727670512title">Funding Statement</a></li><li><a href="#idm140359727667536title">Data Availability</a></li><li><a href="#idm140359726955744title">References</a></li></ul></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr>Articles from <span class="acknowledgment-journal-title">PLoS ONE</span> are provided here courtesy of <strong>Public Library of Science</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC4368747/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC4368747/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC4368747/pdf/pone.0118553.pdf">PDF (690K)</a></li> | <li><a href="#" data-citationid="PMC4368747" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4368747%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4368747%2F&amp;text=Validation%20of%20a%20Rapid%20and%20Sensitive%20LC-MS%2FMS%20Method%20for%20Determination%20of%20Exemestane%20and%20Its%20Metabolites%2C%2017%CE%B2-Hydroxyexemestane%20and%2017%CE%B2-Hydroxyexemestane-17-O-%CE%B2-D-Glucuronide%3A%20Application%20to%20Human%20Pharmacokinetics%20Study" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4368747%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="25793887" data-aiid="4368747" data-aid="4368747" data-iid="250028" data-domainid="440" data-domain="plosone" data-accid="PMC4368747" data-md5="98cb7e4de982ec30c05f1f40bd59d0d7">

<div>


</div>   
    </div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"><div id="body-link-popper-pone.0118553.ref001" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Cancer trends and incidences in Singapore.<div class="authors">Teo MC, Soo KC</div><div class="citation">Jpn J Clin Oncol. 2013 Mar; 43(3):219-24.</div><p>[<a href="/pubmed/23303840/" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0118553.ref001">Ref list</a>]</p></div><div id="body-link-popper-pone.0118553.ref002" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Efficacy of exemestane after nonsteroidal aromatase inhibitor use in metastatic breast cancer patients.<div class="authors">Kim SH, Park IH, Lee H, Lee KS, Nam BH, Ro J</div><div class="citation">Asian Pac J Cancer Prev. 2012; 13(3):979-83.</div><p>[<a href="/pubmed/22631683/" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0118553.ref002">Ref list</a>]</p></div><div id="body-link-popper-pone.0118553.ref006" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.<div class="authors">Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP</div><div class="citation">J Clin Oncol. 2002 Aug 1; 20(15):3317-27.</div><p>[<a href="/pubmed/12149306/" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0118553.ref006">Ref list</a>]</p></div><div id="body-link-popper-pone.0118553.ref007" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Experience with exemestane in the treatment of early and advanced breast cancer.<div class="authors">Lønning PE, Geisler J</div><div class="citation">Expert Opin Drug Metab Toxicol. 2008 Jul; 4(7):987-97.</div><p>[<a href="/pubmed/18624685/" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0118553.ref007">Ref list</a>]</p></div><div id="body-link-popper-pone.0118553.ref008" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.<div class="authors">Kittaneh M, Glück S</div><div class="citation">Breast Cancer (Auckl). 2011; 5():209-26.</div><p>[<a href="/pubmed/22084574/" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0118553.ref008">Ref list</a>]</p></div><div id="body-link-popper-pone.0118553.ref009" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.<div class="authors">Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI</div><div class="citation">Cancer Treat Rev. 2008 Apr; 34(2):157-74.</div><p>[<a href="/pubmed/18164821/" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0118553.ref009">Ref list</a>]</p></div><div id="body-link-popper-pone.0118553.ref013" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Aromatase inhibitors in the breast cancer clinic: focus on exemestane.<div class="authors">Van Asten K, Neven P, Lintermans A, Wildiers H, Paridaens R</div><div class="citation">Endocr Relat Cancer. 2014 Feb; 21(1):R31-49.</div><p>[<a href="/pubmed/24434719/" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0118553.ref013">Ref list</a>]</p></div><div id="body-link-popper-pone.0118553.ref014" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Detection of new urinary exemestane metabolites by gas chromatography coupled to mass spectrometry.<div class="authors">Cavalcanti Gde A, Garrido BC, Leal FD, Padilha MC, de la Torre X, de Aquino Neto FR</div><div class="citation">Steroids. 2011 Sep-Oct; 76(10-11):1010-5.</div><p>[<a href="/pubmed/21530565/" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0118553.ref014">Ref list</a>]</p></div><div id="body-link-popper-pone.0118553.ref015" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">In vitro cytochrome P450-mediated metabolism of exemestane.<div class="authors">Kamdem LK, Flockhart DA, Desta Z</div><div class="citation">Drug Metab Dispos. 2011 Jan; 39(1):98-105.</div><p>[<a href="/pubmed/20876785/" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0118553.ref015">Ref list</a>]</p></div><div id="body-link-popper-pone.0118553.ref016" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.<div class="authors">Sun D, Chen G, Dellinger RW, Sharma AK, Lazarus P</div><div class="citation">Pharmacogenet Genomics. 2010 Oct; 20(10):575-85.</div><p>[<a href="/pubmed/20697310/" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0118553.ref016">Ref list</a>]</p></div><div id="body-link-popper-pone.0118553.ref017" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.<div class="authors">Wong NS, Seah EZh, Wang LZ, Yeo WL, Yap HL, Chuah B, Lim YW, Ang PC, Tai BC, Lim R, Goh BC, Lee SC</div><div class="citation">Pharmacogenet Genomics. 2011 Nov; 21(11):760-8.</div><p>[<a href="/pubmed/21849928/" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0118553.ref017">Ref list</a>]</p></div><div id="body-link-popper-pone.0118553.ref018" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection.<div class="authors">Breda M, Pianezzola E, Benedetti MS</div><div class="citation">J Chromatogr. 1993 Oct 29; 620(2):225-31.</div><p>[<a href="/pubmed/8300790/" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0118553.ref018">Ref list</a>]</p></div><div id="body-link-popper-pone.0118553.ref019" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma.<div class="authors">Corona G, Elia C, Casetta B, Diana C, Rosalen S, Bari M, Toffoli G</div><div class="citation">J Mass Spectrom. 2009 Jun; 44(6):920-8.</div><p>[<a href="/pubmed/19214962/" ref="reftype=pubmed&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">PubMed</a>] [<a href="#pone.0118553.ref019">Ref list</a>]</p></div><div id="body-link-popper-pone.0118553.ref020" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">20. <span class="mixed-citation">Guidance for Industry Bioanalytical Method Validation. Available: <a href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=4368747&amp;issue-id=250028&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf</a>
</span> [<a href="#pone.0118553.ref020">Ref list</a>]</div></div>
                        </div>
                        <div class="bottom">
                            
                            

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 64px; left: 459px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: block;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: block;">Turn off</a></div></div><div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript>&lt;img alt="statistics" src="/stat?jsdisabled=true&amp;amp;ncbi_db=pmc&amp;amp;ncbi_pdid=article&amp;amp;ncbi_acc=&amp;amp;ncbi_domain=plosone&amp;amp;ncbi_report=record&amp;amp;ncbi_type=fulltext&amp;amp;ncbi_objectid=&amp;amp;ncbi_pcid=/articles/PMC4368747/&amp;amp;ncbi_app=pmc" /&gt;</noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- 95B63906E70AD421_0000SID /projects/PMC/PMCViewer@4.46 ptpmc102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" style="display: none;" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div></body></htm
